Stay updated with breaking news from Scientific Plenary. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Late-breaking oral presentation of a subgroup analysis in RAMP 201 Part A heavily pretreated patients receiving avutometinib and defactinib and their best response compared to most recent prior...
- Eisai Co., Ltd. announced today the presentation of two abstracts at the Society of Gynecologic Oncology 2023 Annual Meeting on Women's Cancer , which is taking place in-person in Tampa, Florida... | March 24, 2023
Trial Met Primary Endpoint with Confirmed Objective Response Rate of 32.4%, including 5 Complete Responses; Updated Median Duration of Response of 6.9
NEWTON, Mass. - Karyopharm Therapeutics Inc. , a commercial-stage pharmaceutical company pioneering novel cancer therapies, announced that results from the Phase 3 SIENDO study will be presented at... | March 17, 2022
/PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that...